Impact of histamine type-2 receptor antagonists on the anticancer efficacy of gefitinib in patients with non-small cell lung cancer

Autor: Hirotoshi Dosaka-Akita, Naofumi Shinagawa, Masaki Kobayashi, Yoh Takekuma, Yasushi Shimizu, Mitsuru Sugawara, Ichiro Kinoshita, Ken Iseki, Yoshitaka Saito
Jazyk: angličtina
Rok vydání: 2020
Předmět:
Adult
Male
Oncology
medicine.medical_specialty
Lung Neoplasms
Histamine type-2 receptor antagonists (H2RAs)
EGFR
Antineoplastic Agents
030226 pharmacology & pharmacy
03 medical and health sciences
0302 clinical medicine
Gefitinib
Non-small cell lung cancer
Carcinoma
Non-Small-Cell Lung
Internal medicine
medicine
Clinical endpoint
Humans
Drug Interactions
Pharmacology (medical)
030212 general & internal medicine
Epidermal growth factor receptor
Adverse effect
Lung cancer
neoplasms
Aged
Retrospective Studies
Aged
80 and over
Pharmacology
biology
business.industry
Hazard ratio
Cancer
General Medicine
Middle Aged
medicine.disease
Progression-Free Survival
respiratory tract diseases
Acid suppressants (AS)
Survival Rate
Histamine H2 Antagonists
Concomitant
biology.protein
Female
Antacids
business
medicine.drug
Zdroj: European Journal of Clinical Pharmacology. 77:381-388
ISSN: 0031-6970
Popis: Purpose Gefitinib is one of the standard treatments for non-small cell lung cancer (NSCLC) with epidermal growth factor receptor mutations. It has been reported that acid suppressants (AS) decrease the anti-tumor effect of gefitinib by reducing its solubility. AS is sometimes necessary in cancer patients; however, previous reports have not shown the most compatible AS with gefitinib administration in cancer patients. This study was conducted to determine if histamine type 2 receptor antagonists (H2RAs) can affect the anti-tumor efficacy of gefitinib. Methods Eighty-seven patients with NSCLC who were administered gefitinib were retrospectively investigated. Patients who were co-administered H2RA were compared with non-AS control patients. H2RA was administered once a day at about 3-5 or 8-12 h after gefitinib intake. The primary endpoint of this study was progression-free survival (PFS), and secondary endpoints were overall survival (OS), overall response rate (ORR), and adverse effects. Results Median PFS in H2RA group and control group was 8.0 months and 9.0 months, respectively, with no significant difference (p = 0.82). The incidence of liver dysfunction was significantly less in patients administered H2RA, whereas there were no differences between the two groups with regard to skin toxicity and diarrhea. Multivariate analysis suggested that H2RA co-administration is not a risk factor for worse PFS and OS (hazard ratio of 0.95, 0.86; 95% confidence interval of 0.60-1.48, 0.52-1.43;p = 0.82 and 0.60, respectively). Conclusion This study demonstrated that concomitant administration of H2RA with gefitinib does not affect the efficacy of gefitinib.
Databáze: OpenAIRE
Externí odkaz: